RxDoctor Payments Data

Pradeep Patel, MD

Family Medicine · Monroe, NCNPI 1255534343

Payments from drug & device makers

$419in general payments, 2019–2025

Across 11 payments — averaging $38.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$128
  • Galderma Laboratories, L.p.$80
  • Eisai Inc.$61
  • Merck$49
  • AstraZeneca$49
  • AbbVie$26
  • plus $26 from 1 others

What the payments were for

  • Food & beverage$419100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$419 in reported general payments places this provider in the 55th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$113,939
Medicare patients
256
Services billed
936

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban328$92,486
CreonLipase/Protease/Amylase15$23,825
OzempicSemaglutide23$23,256
TrulicityDulaglutide23$14,063
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr24$11,779
SantylCollagenase Clostridium Hist.24$11,171
JanuviaSitagliptin Phosphate36$10,346
LinzessLinaclotide14$9,187
JardianceEmpagliflozin30$9,082
Sevelamer Carbonate39$7,615
ArexvyRsvpref3 Antigen/As01e/Pf24$7,507
TradjentaLinagliptin24$6,314
Gabapentin179$5,315
XareltoRivaroxaban19$5,223
Atorvastatin Calcium261$4,727

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$26$33,01229 claims
MerckJanuvia$49$10,34636 claims
AstraZenecaFarxiga$49$4,06614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Monroe

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →